BioMerieux SA
EYWN
Company Profile
Business description
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
Contact
Marcy l’Etoile
Lyon69280
FRAT: +33 478872000
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
15,226
Stocks News & Analysis
stocks
SpaceX is scaling AI infrastructure on earth, data centers in space might be next
Our view on the first results as a publicly traded company.
stocks
Investors too optimistic about overvalued ASX share
Upgraded first-half revenue guidance at the upper end of the previously announced range.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,896.10 | 60.50 | -0.68% |
| CAC 40 | 7,921.68 | 83.19 | 1.06% |
| DAX 40 | 25,645.04 | 340.62 | 1.35% |
| Dow JONES (US) | 52,856.09 | 360.21 | 0.69% |
| FTSE 100 | 10,752.88 | 19.88 | 0.19% |
| HKSE | 23,651.87 | 215.87 | -0.90% |
| NASDAQ | 26,702.86 | 278.04 | 1.05% |
| Nikkei 225 | 64,253.00 | 368.24 | -0.57% |
| NZX 50 Index | 13,695.24 | 66.05 | -0.48% |
| S&P 500 | 7,757.17 | 44.60 | 0.58% |
| S&P/ASX 200 | 8,770.00 | 61.30 | -0.69% |
| SSE Composite Index | 3,712.83 | 0.20 | -0.01% |